![Neil Torres](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Neil Torres
Direttore/Membro del Consiglio presso
Systems Oncology LLC
Profilo
Neil Torres is currently the Director at Systems Oncology LLC and Principal at The Pritzker Organization LLC since 2002.
Mr. Torres completed undergraduate education at The University of Chicago in 2002.
Posizioni attive di Neil Torres
| Società | Posizione | Inizio |
|---|---|---|
Systems Oncology LLC
 Systems Oncology LLC BiotechnologyHealth Technology Researches and develops cancer drugs | Direttore/Membro del Consiglio | - |
The Pritzker Organization LLC
 The Pritzker Organization LLC Investment ManagersFinance The Pritzker Organization invests in companies located in the United States with an enterprise value of USD 100 - 1000 billion and an EBITDA of USD 10 - 150 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for growth stage capital requirements with an investment size of USD 75 -300 million for majority deals & USD 15 - 100 million for minority and structured deals. The firm also acquires majority and minority interest. | Investitore di Private Equity | 01/06/2002 |
Formazione di Neil Torres
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
98
Relazioni di 1° grado
3
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pritzker Organization LLC
The Pritzker Organization LLC Investment ManagersFinance The Pritzker Organization invests in companies located in the United States with an enterprise value of USD 100 - 1000 billion and an EBITDA of USD 10 - 150 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing for growth stage capital requirements with an investment size of USD 75 -300 million for majority deals & USD 15 - 100 million for minority and structured deals. The firm also acquires majority and minority interest. | Finance |
Systems Oncology LLC
Systems Oncology LLC BiotechnologyHealth Technology Researches and develops cancer drugs | Health Technology |
